2.00Open2.00Pre Close0 Volume14 Open Interest7.50Strike Price0.00Turnover812.69%IV-77.99%PremiumJan 17, 2025Expiry Date4.41Intrinsic Value100Multiplier13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4273Delta0.0833Gamma0.56Leverage Ratio-0.0730Theta-0.0019Rho-0.24Eff Leverage0.0023Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet